Calithera Biosciences Inc
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences Inc (CALA) - Total Assets
Latest total assets as of December 2022: $28.68 Million USD
Based on the latest financial reports, Calithera Biosciences Inc (CALA) holds total assets worth $28.68 Million USD as of December 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Calithera Biosciences Inc - Total Assets Trend (2012–2022)
This chart illustrates how Calithera Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Calithera Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Calithera Biosciences Inc's total assets of $28.68 Million consist of 92.8% current assets and 7.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2022)
This chart illustrates how Calithera Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Calithera Biosciences Inc's current assets represent 92.8% of total assets in 2022, an increase from 74.3% in 2012.
- Cash Position: Cash and equivalents constituted 88.8% of total assets in 2022, up from 72.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Calithera Biosciences Inc Competitors by Total Assets
Key competitors of Calithera Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
Calithera Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Calithera Biosciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Calithera Biosciences Inc is currently not profitable relative to its asset base.
Calithera Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.60 | 4.39 | 5.27 |
| Quick Ratio | 3.60 | 4.39 | 5.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $19.23 Million | $ 47.45 Million | $ 126.22 Million |
Calithera Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Calithera Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.07 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -55.7% |
| Total Assets | $28.68 Million |
| Market Capitalization | $1.46K USD |
Valuation Analysis
Below Book Valuation: The market values Calithera Biosciences Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Calithera Biosciences Inc's assets decreased by 55.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Calithera Biosciences Inc (2012–2022)
The table below shows the annual total assets of Calithera Biosciences Inc from 2012 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $28.68 Million | -55.72% |
| 2021-12-31 | $64.76 Million | -48.44% |
| 2020-12-31 | $125.59 Million | -25.59% |
| 2019-12-31 | $168.77 Million | +18.25% |
| 2018-12-31 | $142.72 Million | -25.84% |
| 2017-12-31 | $192.46 Million | +251.22% |
| 2016-12-31 | $54.80 Million | -27.66% |
| 2015-12-31 | $75.75 Million | -27.70% |
| 2014-12-31 | $104.77 Million | +200.68% |
| 2013-12-31 | $34.84 Million | +1038.69% |
| 2012-12-31 | $3.06 Million | -- |